Biologic Utilization Patterns: Data from the International Severe Asthma Registry (ISAR)

A. Menzies-Gow, E. Wang, M. Rowlands, M. Alacqua, M. Al-Ahmad, L. Bulathsinhala, V. Carter, I. Chaudhry, T Cheng, B. G. Cosio, N. Eleangovan, J. M. FitzGerald, L. G Heaney, M. Hew, N. Hossein, D.J. Jackson, M. Kallieri, D. Larenas-Linnemann, S. Loukides, N. LugogoR. Murray, A. Papaioannou, L. Perez de Llano, C. Porsbjerg, L. Rasmussen, J. Schmid, T. N Tran, C. S. Ulrik, J. W Upham, D. B. Price

Research output: Contribution to journalAbstractpeer-review

Abstract

Rationale: Use of biologics in severe asthma has grown dramatically in the last decade; however, little is known about the patterns of biologic use in real-life.
Original languageEnglish
Article numberA7739
Number of pages2
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume201
Issue numberD103
DOIs
Publication statusPublished - 2020

Bibliographical note

This abstract is funded by: ISAR is conducted by Optimum Patient Care Global Limited, and co-funded by OPC Global and AstraZeneca

Fingerprint

Dive into the research topics of 'Biologic Utilization Patterns: Data from the International Severe Asthma Registry (ISAR)'. Together they form a unique fingerprint.

Cite this